Aggressive Trading Strategies

[globewatcher]

IMNR news...
==================
(COMTEX) B: The Immune Response Corporation's NeuroVax(TM) Demonstrates Strong Results in Phase I/II Study in Multiple Sclerosis - Phase I/II Clinical Trial Discontinued
arly After 94 Percent of Patients Show Response - - Results Presented at American Academy of Neurology -

(PRNewswire-FirstCall )

CARLSBAD, Calif., Apr 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- The Immune
Response Corporation (Nasdaq: IMNR), a biopharmaceutical company developing
immune-based therapies (IBT) for HIV and select other diseases, today announced
that its investigational T-cell receptor (TCR) peptide vaccine, NeuroVax(TM),
produced a peptide-specific immune response in 94 percent of the patients
treated in a Phase I/II clinical trial in multiple sclerosis. Results of the
three-armed, randomized trial, which was discontinued early when an interim
analysis revealed the high rate of response, were presented yesterday at the
54th annual meeting of the American Academy of Neurology (AAN) held in San
Francisco, CA.

Earlier clinical research on immunotherapy for multiple sclerosis suggested that
only about half of patients had an immune response to treatment with a single
TCR peptide but that this reaction probably had clinical benefit. NeuroVax(TM)
is composed of a combination of TCR peptides from three families (BV5S2, BV6S5,
and BV13S1) with an adjuvant to improve immune response rates.

"The surprisingly high immunogenic response to NeuroVax(TM), both in the
percentage of patients responding and in the strength of their responses,
validates this new approach to enhancing TCR peptide immunization and suggests
that we may finally be able to more specifically regulate the pathogenic T-cells
thus addressing the underlying causes of the disease," said Dennis N. Bourdette,
MD, Chairman of the Department of Neurology at Oregon Health & Science
University in Portland, Ore., and lead investigator for this study. "Patients
with multiple sclerosis currently have few treatment options. Our research is
continuing to determine if the active immune response to NeuroVax(TM) correlates
with a clinically relevant impact on disease progression."

In the study, 37 patients were randomized to receive either the three TCR
peptides with saline (15 patients), the NeuroVax(TM) combination (16 patients),
or adjuvant alone (6 patients). Patients received monthly injections for 24
weeks, and the induction of TCR peptide-specific T-cell responses was measured
against baseline to gauge immune response. Using an intent-to-treat analysis,
the proportion of patients who were TCR vaccine responders was significantly
greater (p<0.001) in the NeuroVax(TM) group, with 15/16 (94 percent) responding
patients compared with 1/15 (7 percent) for the TCR/saline group and 0/6 for the
adjuvant group.

"With 94 percent of patients showing a disease-specific immune response in this
study, we will continue to pursue development of NeuroVax(TM) in multiple
sclerosis as both a monotherapy and in combination with currently approved
treatments," said John N. Bonfiglio Ph.D., Chief Executive Officer of The Immune
Response Corporation. "NeuroVax(TM) is another example of how immune-based
therapies pioneered by The Immune Response Corporation's co-founder, Dr. Jonas
Salk, may provide a promising new mechanism for fighting difficult diseases.
Together with our product candidates for HIV -- REMUNE(R) and IR103 -- I believe
our pipeline is making the progress necessary to eventually commercialize
products to meet patient needs in two underserved areas."

NeuroVax(TM) was well tolerated over the 24 weeks of therapy. There were no
serious side effects reported, and the only adverse events attributable to
NeuroVax(TM) were injection-site reactions.

Multiple sclerosis is an autoimmune disease in which the immune system, the
body's principal defense against foreign substances such as bacteria, mistakenly
attacks normal tissues of the central nervous system. It afflicts approximately
400,000 people in the United States and more than 2.5 million worldwide.
Specifically, the disease results in the loss of a fatty tissue called myelin
that surrounds and protects nerve fibers, creating scarring (sclerosis) that
interferes with the normal transmission of nerve impulses. This, in turn, leads
to a variety of highly individual and unpredictable neurological symptoms,
ranging from movement and balance problems to vision impairment. It is believed
that a subset of the specific class of white blood cells, CD4+ T-cells, that
normally plays an important role in the immune system, somehow becomes
autoreactive and is principally responsible for the progression of the disease.
TCR peptides have been shown to stimulate regulatory T-cells capable of
suppressing the autoreactive CD4+ T-cells in a certain proportion of patients.
NeuroVax(TM), which combines three TCR peptides with an adjuvant, was designed
to increase the likelihood of this immune reaction.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR) is developing immune-based
therapies (IBT) for HIV and select other diseases. The Company's HIV products
are based on its patented whole-killed virus technology, co-invented by Company
founder, Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE(R), currently
in Phase II, is being developed as a treatment for people with HIV. The Company
has initiated development of a new IBT, IR103, which incorporates a
second-generation immunostimulatory oligonucleotide adjuvant.

The Immune Response Corporation is also developing an IBT for multiple sclerosis
(MS), NeuroVax(TM), which is currently in Phase II and has shown potential
therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation on the World Wide Web at
www.imnr.com

About OHSU

Oregon Health & Science University, located in Portland, Ore., includes the
schools of dentistry, medicine, nursing and science and engineering; OHSU
Hospital and Doernbecher Children's Hospital; numerous primary care and
specialty clinics; multiple research institutes; and several outreach and
community service units.

This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could, will,
might, plan, projection, forecast, expect, guidance, potential and developing.
Actual results could vary materially from those expected due to a variety of
risk factors, including whether the Company will continue as a going concern and
successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103,
the uncertainty of successful completion of any such clinical trials, the fact
that the Company has not succeeded in commercializing any drug, the risk that
REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a
therapeutic or preventive vaccine, whether future trials will be conducted and
whether the results of such trials will coincide with the results of REMUNE(R),
NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials.
These risks, among others, are set forth in The Immune Response Corporation's
SEC filings including, but not limited to, its Annual Report on Form 10-K for
the year ended December 31, 2003, and any subsequent Quarterly Reports on Form
10-Q. The Company undertakes no obligation to update the results of these
forward-looking statements to reflect events or circumstances after today or to
reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.



MEDIA CONTACT:
Laura Silver, Sam Brown Inc. Corporate Communications
310-551-9940
[e-mail]

INVESTOR RELATIONS CONTACT:
Kathy Waller, Financial Relations Board
312-266-7800
[e-mail]

AT THE COMPANY:
Michael K. Green, Chief Financial Officer
760-431-7080
[e-mail]

AT OHSU:
Jonathan Modie, media relations coordinator
503-494-8231
[e-mail]

SOURCE The Immune Response Corporation


CONTACT: Media, Laura Silver, Corporate Communications of Sam Brown
Inc., [phone], [e-mail]; or Investor Relat
ons, Kathy
Waller of Financial Relations Board, [phone],
[e-mail], both for The Immune Resp
nse Corporation;
or Michael K. Green, Chief Financial Officer of The Immune Re
ponse
Corporation, [phone], [e-mail]; or Jonathan Modi
, media
relations coordinator of OHSU, [phone], modiej@ohsu.e
u

URL: http://www.imnr.com
http://www.prnewswire.com

Copyright (C) 2004 PR Newswire. All rights reserved.

-0-


KEYWORD: California
Oregon
INDUSTRY KEYWORD: HEA
MTC
BIO
SUBJECT CODE: SVY

*** end of story ***